To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) 70 days post last dose of study drug [clinicaltrials_resource:b53dfd14f928cb7382fc9e23721a7f44]
These will be measured only at selected study sites and for subsets of selected tumors, and are very exploratory in nature
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) 70 days post last dose of study drug [clinicaltrials_resource:b53dfd14f928cb7382fc9e23721a7f44]
These will be measured only at selected study sites and for subsets of selected tumors, and are very exploratory in nature
Bio2RDF identifier
b53dfd14f928cb7382fc9e23721a7f44
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b53dfd14f928cb7382fc9e23721a7f44
measure [clinicaltrials_vocabulary:measure]
To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106)
time frame [clinicaltrials_vocabulary:time-frame]
70 days post last dose of study drug
description
These will be measured only at ...... are very exploratory in nature
identifier
clinicaltrials_resource:b53dfd14f928cb7382fc9e23721a7f44
title
To characterize the safety and ...... s post last dose of study drug
@en
type
label
To characterize the safety and ...... dfd14f928cb7382fc9e23721a7f44]
@en